Limitations of cholesterol lowering with PCSK9 inhibitors
Open Access
- 1 April 2017
- journal article
- editorial
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 5 (4) , 241-243
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG studyThe Lancet Diabetes & Endocrinology, 2017
- Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experienceCurrent Opinion in Lipidology, 2016
- HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United KingdomAtherosclerosis, 2016
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With HypercholesterolemiaAnnals of Internal Medicine, 2015
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialThe Lancet, 2015
- A 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaNew England Journal of Medicine, 2014
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 studyThe Lancet, 2012
- The biology and therapeutic targeting of the proprotein convertasesNature Reviews Drug Discovery, 2012
- Unravelling the functional significance of PCSK9Current Opinion in Lipidology, 2007